|
|
|
|
|
| Laser-assisted technology and a 5-day process give patients a new lease on life. |
|
|
| $25,000 grant given in honor of Veterans Day. |
|
|
| A new book called THE TRUTH, by award-winning author Stephen Hawley Martin, draws upon research by impeccable mainstream sources to overturn the widely-held belief that awareness and mind are products of the brain. |
|
|
| Steven S. Scherer, MD, PHD, Professor of Neurology at the University of Pennsylvania, and Herb Beron, a Senior Vice President for Citigroup Smith Barney, have joined the Charcot-Marie-Tooth Association Board of Directors. |
|
|
| LegalView recently used its traumatic brain injury blog to report of a severely debilitating condition that can be derived from a brain injury and may cause complete paralysis of a patient. The condition is known as locked-in syndrome, and while it is rare, there is no cure available for current and future victims. |
|
|
| United States therapeutic apheresis market is forecast to reach $103 million by 2012. Increasing alliances and agreements and research for new procedures and more sophisticated applications would drive future growth of the market. |
|
|
| A new website launched by the American Health Assistance Foundation (AHAF) is dedicated to helping the millions of people affected by Alzheimer's disease, macular degeneration and glaucoma. |
|
|
| Representatives from the Collaborative on Health and the Environment (CHE) and Parkinson's Action Network (PAN) today released an executive summary of the consensus statement on "Parkinson's Disease (PD) and the Environment," which was recently published on-line in Environmental Health Perspectives (EHP), the peer-reviewed journal of the National Institute of Environmental Health Sciences. In addition, a primer detailing the scientific and medical context of the consensus statement findings was released. |
|
|
| The HeadMinder web-based Cognitive Stability Index (CSI) has proven more useful for blast-concussion detection than the ANAM computerized test battery the DoD currently employs. The CSI provides an immediate solution to clear the backlog of 400,000 IED-exposed service members in less than two years. |
|
|
| Osmotica Pharmaceutical Corp. is announcing that Venlafaxine Extended-Release Tablets, 37.5 mg, 75 mg, 150 mg, and 225 mg, which was approved by the U.S. Food and Drug Administration in May, is now commercially available through its marketing partner, Upstate Pharma, LLC, a subsidiary of UCB, Inc. Shipments of the product to wholesalers and other commercial outlets began September 30, 2008 and promotion of the product will commence later in the month. Forrest Waldon, CEO of Osmotica Pharmaceutical stated, “We are excited about the launch of this innovative product and look forward to... |
|
|
